Skip to main content

Drug Interactions between pneumococcal 23-polyvalent vaccine and zoster vaccine live

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

pneumococcal 23-polyvalent vaccine zoster vaccine live

Applies to: pneumococcal 23-polyvalent vaccine and zoster vaccine live

ADJUST DOSING INTERVAL: Concomitant administration of pneumococcal 23-valent vaccine may reduce the immunogenicity of varicella-zoster virus (VZV) vaccine. The mechanism of interaction has not been described. In a randomized, double-blind, controlled clinical trial consisting of 473 adults sixty years of age or older, VZV antibody levels were significantly lower in the subjects who received both vaccines concurrently than in those who were given VZV vaccine four weeks after the pneumococcal 23-valent vaccine. At four weeks postvaccination, VZV antibody geometric mean titers were 338 gpELISA units/mL for the concomitant group and 484 gpELISA units/mL for the sequential group (GMT ratio = 0.70).

MANAGEMENT: Varicella-zoster virus vaccine and pneumococcal 23-valent vaccine should not be given concurrently. If possible, these vaccines should be administered at least four weeks apart.

References (1)
  1. (2006) "Product Information. Zostavax (zoster vaccine live)." Merck & Co., Inc

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer